Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tirzepatide Cuts Body Weight in Japanese Adults with Obesity: PIII
October 23, 2024
- CEA Is “Wrong Tool” That Doesn’t Fit into Japanese System: J&J Exec
October 23, 2024
- Takeda to Offer Buyout Package from December as Part of Reorganization
October 22, 2024
- Aculys Pharma’s Pitolisant Nets Positive Data in Japan PIII
October 22, 2024
- Astellas’ Gastric Cancer Med Vyloy Approved in US after Re-Filing
October 22, 2024
- Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
- GSK Japan Targets 8% Average Annual Growth through 2031
October 21, 2024
- Ferring Japan Set for 15% Annual Growth as It Gazes at Gene Therapy Debut
October 21, 2024
- Real-World Data Confirms Efficacy of Cefiderocol in Drug-Resistant Bacteria
October 18, 2024
- Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
- Doshisha Offshoot Eyes Nationwide Delivery of Cryopreserved Cell Product for Bullous Keratopathy
October 17, 2024
- Eisai Alzheimer’s Drug Hits Another Snag, This Time in Australia
October 17, 2024
- Shinya Nagase Named New Skipper of BD Japan
October 17, 2024
- Ultragenyx Looks to Launch 6 New Products in Japan by 2028-End: CCO
October 17, 2024
- Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
- Teclistamab Shows Sustained Responses in Japanese MM Patients: J&J
October 16, 2024
- CarbGeM Ties Up with University of Zurich on Bacterial Persistence Research
October 16, 2024
- Enhertu Gets Conditional Nod for Lung Cancer in China
October 16, 2024
- Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
October 15, 2024
- Lilly CEO Touts Benefits of Early AD Drug Kisunla
October 15, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…